Zai Lab Ltd (ZLAB) Financial Statements (2025 and earlier)

Company Profile

Business Address 4560 JINKE ROAD
SHANGHAI,
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments779,667806,4511,008,4701,409,1001,186,792
Cash and cash equivalent449,667790,1511,008,470964,100442,116
Short-term investments 330,00016,300 445,000744,676
Restricted cash and investments100,000    
Receivables85,17859,19939,96354,8095,165
Inventory, net of allowances, customer advances and progress billings39,87544,82731,62118,95113,144
Inventory39,87544,82731,62118,95113,144
Financing receivable, excluding accrued interest, after allowance for credit loss6,1348,608 
Other undisclosed current assets45,76022,99535,67418,02110,935
Total current assets:1,050,480939,6061,124,3361,500,8811,216,036
Noncurrent Assets
Operating lease, right-of-use asset21,49614,84419,51214,18917,701
Nontrade receivables 1,351  23,85822,141
Property, plant and equipment47,96153,73457,86343,10229,162
Long-term investments and receivables 3,1159,2206,43115,6051,279
Long-term investments 3,1159,2206,43115,6051,279
Intangible assets, net (including goodwill)56,02713,3891,5111,8481,532
Intangible assets, net (excluding goodwill)56,02713,3891,5111,8481,532
Deposits noncurrent assets 1,2841,2091,396870862
Restricted cash and investments1,1141,113803803743
Other noncurrent assets     
Other undisclosed noncurrent assets2,9253,1808,2888,8008,182
Total noncurrent assets:135,27396,68995,804109,07581,602
TOTAL ASSETS:1,185,7531,036,2951,220,1401,609,9561,297,638
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities100,906112,99165,974126,16362,641
Accounts payable100,906112,99165,974126,16362,641
Debt131,711    
Other liabilities58,72082,97266,81860,81130,196
Other undisclosed current liabilities8,0487,1047,0505,9275,206
Total current liabilities:299,385203,067139,842192,90198,043
Noncurrent Liabilities
Long-term debt and lease obligation:    9,61313,392
Liabilities, other than long-term debt45,47037,11034,703  
Deferred revenue31,43328,73821,360  
Other liabilities325325   
Operating lease, liability13,7128,04713,3439,61313,392
Other undisclosed noncurrent liabilities    17,8733,466
Total noncurrent liabilities:45,47037,11034,70337,09930,250
Total liabilities:344,855240,177174,545230,000128,293
Equity
Equity, attributable to parent840,898796,1181,045,5951,379,9561,169,345
Common stock76665
Treasury stock, value(20,836)(20,836)(11,856)(4,279) 
Additional paid in capital3,264,2952,975,3022,893,1202,825,9481,897,467
Accumulated other comprehensive income (loss)50,51537,62625,685(23,645)(14,524)
Accumulated deficit(2,453,083)(2,195,980)(1,861,360)(1,418,074)(713,603)
Total equity:840,898796,1181,045,5951,379,9561,169,345
TOTAL LIABILITIES AND EQUITY:1,185,7531,036,2951,220,1401,609,9561,297,638

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues398,988266,719215,040144,31248,958
Cost of revenue(147,860)(95,816)(74,018)(52,239)(16,736)
Cost of product and service sold(147,118)(1,000)(477)(1,368)(29)
Gross profit:251,128170,903141,02292,07332,222
Operating expenses(533,245)(537,476)(545,379)(792,137)(334,023)
Operating loss:(282,117)(366,573)(404,357)(700,064)(301,801)
Nonoperating income (expense)27,26831,953(38,708)(3,350)34,196
Investment income, nonoperating37,10539,79714,5822,1905,120
Loss, foreign currency transaction, before tax(15,137)(14,850)(56,403)  
Other nonoperating income (expense)5,3007,0063,113(5,540)29,076
Interest and debt expense    (181)
Other undisclosed loss from continuing operations before equity method investments, income taxes(2,254)    
Loss from continuing operations before equity method investments, income taxes:(257,103)(334,620)(443,065)(703,414)(267,786)
Loss from equity method investments   (221)(1,057)(1,119)
Loss from continuing operations:(257,103)(334,620)(443,286)(704,471)(268,905)
Loss before gain (loss) on sale of properties:(704,471)(268,905)
Net loss available to common stockholders, diluted:(257,103)(334,620)(443,286)(704,471)(268,905)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(257,103)(334,620)(443,286)(704,471)(268,905)
Comprehensive loss:(257,103)(334,620)(443,286)(704,471)(268,905)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent12,88911,94149,330(9,121)(19,144)
Comprehensive loss, net of tax, attributable to parent:(244,214)(322,679)(393,956)(713,592)(288,049)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: